Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Company Overview - Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV) and has a broad portfolio that includes drugs for liver diseases, hematology/oncology diseases, and inflammation/respiratory diseases [12] - The company's flagship treatment, Biktarvy, is driving growth within its strong HIV franchise, which generated total sales of $19.6 billion in 2024, reflecting an 8% year-over-year increase [12] Financial Performance - For fiscal 2025, five analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate increasing by$ 0.06 to $7.86 per share [13] - Gilead Sciences has an average earnings surprise of 19.5%, indicating a strong performance relative to expectations [13] Investment Ratings - Gilead Sciences currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B, suggesting a solid overall performance [13][14] - The company also has a Value Style Score of B, supported by attractive valuation metrics such as a forward P/E ratio of 13.31, which may appeal to value investors [13]